Healthy Living Europe
SEE OTHER BRANDS

Keeping up with healthcare and wellness news from Europe

Healthy Living Europe: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthy Living Europe.

Press releases published on August 6, 2025

Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update

– Submitted New Drug Application for vepdegestrant for the treatment of ESR1m, ER+/HER2- advanced or metastatic breast cancer – – Presented ARV-102 SAD and MAD data from the Phase 1 clinical trial in healthy volunteers; initiated dosing in patients with …

Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress

Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress

– On track to report top-line data from Phase 2 trial in chronic rhinosinusitis with nasal polyps (CRSwNP) in the third quarter of 2025 – – Completed enrollment in Phase 2 trial in severe asthma in June 2025; top-line data expected in the first quarter of …

Standard BioTools and Precision Health Research, Singapore (PRECISE-SG100K) Launch Proteomics Collaboration, Selecting SomaScan to Power Large-Scale Population Health Study

Standard BioTools and Precision Health Research, Singapore (PRECISE-SG100K) Launch Proteomics Collaboration, Selecting SomaScan to Power Large-Scale Population Health Study

PRECISE-SG100K will run 100,000 samples as part of an effort to transform precision health and medicine Reinforces SomaScan’s strategic position in the high-impact biobank segment and its increasing role in leading global health initiatives SOUTH SAN …

Fortrea Reports Second Quarter 2025 Results

Fortrea Reports Second Quarter 2025 Results

For the three months ended June 30, 2025, from continuing operations: Revenues of $710.3 million GAAP net loss of $(374.9) million, inclusive of a non-cash goodwill impairment charge Adjusted EBITDA of $54.9 million GAAP and adjusted net (loss) income per …

Evoke Pharma Announces Issuance of New U.S. Patent for GIMOTI With Extended Exclusivity to Late 2038

Evoke Pharma Announces Issuance of New U.S. Patent for GIMOTI With Extended Exclusivity to Late 2038

SOLANA BEACH, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today …

SimpliFed Launches Inaugural National Mastitis Awareness Day During National Breastfeeding Month

SimpliFed Launches Inaugural National Mastitis Awareness Day During National Breastfeeding Month

ITHACA, NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) -- SimpliFed, the leading virtual maternal health leader in breastfeeding and baby feeding support, has launched the first inaugural National Mastitis Awareness Day, on the forest Wednesday in August, …

Forte Medical National Survey Announcement

Forte Medical National Survey Announcement

LONDON, Aug. 06, 2025 (GLOBE NEWSWIRE) -- UK based Medical Technology company Forte Medical is launching a national survey of women in the UK, to ascertain their exposure to urine sampling retests and immediate empirical broad spectrum prescribing, …

Galapagos NV kondigt aan dat GLPG5101 de status van Regenerative Medicine Advanced Therapy (RMAT) van de FDA krijgt voor de behandeling van recidief/refractair mantelcellymfoom

Galapagos NV kondigt aan dat GLPG5101 de status van Regenerative Medicine Advanced Therapy (RMAT) van de FDA krijgt voor de behandeling van recidief/refractair mantelcellymfoom

Mechelen, België; 6 augustus 2025, 7.30 uur CET; gereglementeerde informatie – voorwetenschap – Galapagos NV (Euronext …

ONWARD Medical Announces the Appointment of Lucas Buchanan to its Board of Directors

ONWARD Medical Announces the Appointment of Lucas Buchanan to its Board of Directors

Buchanan is former CFO and COO of Silk Road Medical, where he successfully scaled a growth-stage medical device company, leading to an acquisition by Boston Scientific. Buchanan, formerly a venture capitalist with the Vertical Group, is also an active …

Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Mechelen, Belgium; August 6, 2025, 7:30 CET; regulated information – inside information – Galapagos NV (Euronext …

Communiqué de presse : Sanofi finalise l’acquisition de Vigil Neuroscience, Inc.

Communiqué de presse : Sanofi finalise l’acquisition de Vigil Neuroscience, Inc.

Sanofi finalise l’acquisition de Vigil Neuroscience, Inc. Paris, le 6 août 2025. Sanofi annonce la finalisation de l’acquisition de Vigil Neuroscience, Inc. (« Vigil »). Cette acquisition renforce le pipeline de Sanofi en neurologie avec le VG-3927, un …

Press Release: Sanofi completes the acquisition of Vigil Neuroscience, Inc.

Press Release: Sanofi completes the acquisition of Vigil Neuroscience, Inc.

Sanofi completes the acquisition of Vigil Neuroscience, Inc. Paris, August 6, 2025. Sanofi announces the completion of its acquisition of Vigil Neuroscience, Inc. (“Vigil”). This acquisition strengthens Sanofi’s early-stage pipeline in neurology with VG- …

BriaCell Announces Proposed Effective Date of Share Consolidation

BriaCell Announces Proposed Effective Date of Share Consolidation

PHILADELPHIA and VANCOUVER, British Columbia, Aug. 05, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions